Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Editas Medicine Inc

EDIT
Current price
10.98 USD +0.08 USD (+0.73%)
Last closed 11.05 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 879 625 728 USD
Yield for 12 month +14.26 %
Week
Month
Year
EDIT
21.11.2021 - 28.11.2021

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Address: 11 Hurley Street, Cambridge, MA, United States, 02141

Analytics

WallStreet Target Price

13.53 USD

P/E ratio

Dividend Yield

Current Year

+19 712 000 USD

Last Year

+25 544 000 USD

Current Quarter

+5 336 000 USD

Last Quarter

+2 887 000 USD

Current Year

+19 712 000 USD

Last Year

+25 544 000 USD

Current Quarter

+5 336 000 USD

Last Quarter

+2 887 000 USD

Key Figures EDIT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -202 490 000 USD
Operating Margin TTM -940.09 %
PE Ratio
Return On Assets TTM -25.19 %
PEG Ratio
Return On Equity TTM -50.33 %
Wall Street Target Price 13.53 USD
Revenue TTM 24 610 000 USD
Book Value 4.41 USD
Revenue Per Share TTM 0.34 USD
Dividend Share
Quarterly Revenue Growth YOY 12604.8 %
Dividend Yield
Gross Profit TTM -155 246 000 USD
Earnings Share -2.69 USD
Diluted Eps TTM -2.69 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics EDIT

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History EDIT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation EDIT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 22.9427
Price Sales TTM 35.7426
Enterprise Value EBITDA -2.7884
Price Book MRQ 2.4403

Financials EDIT

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators EDIT

For 52 weeks

6.08 USD 11.93 USD
50 Day MA 7.92 USD
Shares Short Prior Month 16 769 060
200 Day MA 8.47 USD
Short Ratio 9.28
Shares Short 15 872 497
Short Percent 27.33 %